UBR4 enhances efficacy of anti-EGFR antibody by facilitating clathrin-dependent EGFR endocytosis in colorectal cancer
Journal of Gastroenterology · 2026
DOI: 10.1007/s00535-025-02338-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Akira Fukuya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima, 770-8503,…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Endocytosis, Cetuximab, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
BACKGROUND: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) effectively treat metastatic colorectal cancer (CRC); however, predicting response to these therapies remains challenging. Here, we aimed to identify key regulators of EGFR internalization as predictive biomarkers for anti-EGFR mAb therapy in CRC. METHODS: CRC cell lines were treated with cetuximab and EGFR internalization was analyzed using siRNA knockdowns, inhibitors, and proteomic analyses. Key proteins mediating cetuximab-bound EGFR internalization were identified through immunoprecipitation and tandem mass spectrometry and validated using RT-PCR, co-immunoprecipitation, immunofluorescence, cell viability, and apoptosis assays. Immunohistochemistry was performed to correlate findings with clinical outcomes. RESULTS: Clathrin-dependent endocytosis mediated by Clathrin Heavy Chain was the primary pathway of cetuximab-bound EGFR internalization. Knockdown of clathrin-independent endocytosis genes or inhibition of macropinocytosis did not affect cetuximab-bound EGFR internalization. Ubiquitin Protein Ligase E3 Component N-Recognin 4 (UBR4) was identified as a critical mediator of EGFR degradation. UBR4 knockdown promoted EGFR recycling, enhanced cell proliferation, and reduced apoptosis in response to cetuximab. High UBR4 expression in CRC tissues correlated with better responses and longer progression-free survival in patients treated with anti-EGFR mAb therapy. CONCLUSIONS: UBR4 promotes clathrin-dependent EGFR degradation, enhancing anti-EGFR therapeutic efficacy, and may serve as a predictive biomarker in metastatic CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan.
- Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan. takayama@tokushima-u.ac.jp.
ORCID-Profile: Akira Fukuya, Tetsuji Takayama
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fukuya, A., Sato, Y., Okada, Y., Sagawa, T., Kawano, Y., Bando, M., Okamoto, K., Miyamoto, H., Sogabe, M., & Takayama, T. (2026). UBR4 enhances efficacy of anti-EGFR antibody by facilitating clathrin-dependent EGFR endocytosis in colorectal cancer. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02338-5
Vancouver
Fukuya A, Sato Y, Okada Y, Sagawa T, Kawano Y, Bando M, et al. UBR4 enhances efficacy of anti-EGFR antibody by facilitating clathrin-dependent EGFR endocytosis in colorectal cancer. Journal of Gastroenterology. 2026. doi:10.1007/s00535-025-02338-5
BibTeX
@article{Fukuya2026,
author = {Fukuya, Akira and Sato, Yasushi and Okada, Yasuyuki and Sagawa, Tamotsu and Kawano, Yutaka and Bando, Masahiro and Okamoto, Koichi and Miyamoto, Hiroshi and Sogabe, Masahiro and Takayama, Tetsuji},
title = {UBR4 enhances efficacy of anti-EGFR antibody by facilitating clathrin-dependent EGFR endocytosis in colorectal cancer},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-025-02338-5}
}
EUVIMED